Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03134222 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
A Phase 2 study of Cutaneous Lupus Erythematosus, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 16
- Study locations
NCT03134222 is a Phase 2 study of Cutaneous Lupus Erythematosus that has completed, run by Gilead Sciences. The registered enrollment target is 47 participants. The trial reports 16 study locations across 6 states.
The verdict
NCT03134222, a Phase 2 study of Cutaneous Lupus Erythematosus, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).
Conditions Studied
Interventions
- DRUG Filgotinib
- DRUG Lanraplenib
- DRUG Lanraplenib placebo
- DRUG Filgotinib placebo
Study Locations (16)
California
- Wallace Rheumatic Studies Center - Beverly Hills
- St. Jude Hospital Yorba Linda DBA Dr. Joseph Heritage Healthcare - Fullerton
- Dermatology Research Associates - Los Angeles
- Desert Medical Advances - Palm Desert
- Medderm Associates - San Diego
- Inland Rheumatology Clinical Trials - Upland
Other
- Dermatology Ottawa Research Centre - Ottawa
- University Health Network (UHN) - Toronto Western Hospital - Toronto
- K.Papp Clinical Research - Waterloo
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- Omega Research Consultants LLC - DeBary
North Carolina
- DJL Clinical Research, PLLC - Charlotte
- Wake Forest University Health Sciences - Winston-Salem
Pennsylvania
- Penn State Hershey Medical Center - Hershey
- University of Pennsylvania - Philadelphia
Texas
- Metroplex Clinical Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-05-24 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03134222
The ClinicalTrials.gov registry entry for NCT03134222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Lupus Erythematosus appearing as the primary indexed condition, and to 4 interventions - of which Filgotinib is the first listed.
NCT03134222 reports 16 study locations spanning 6 distinct geographic areas - top geographies include California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT03134222 about?
NCT03134222 is a clinical study titled "Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)". The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).
What is the current status of trial NCT03134222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2017-05-24. Estimated completion is 2019-12-18.
What conditions does trial NCT03134222 study?
This clinical trial studies the following conditions: Cutaneous Lupus Erythematosus.
What interventions are being tested in trial NCT03134222?
The interventions under investigation include: Filgotinib (DRUG), Lanraplenib (DRUG), Lanraplenib placebo (DRUG), Filgotinib placebo (DRUG).
Who is sponsoring clinical trial NCT03134222?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03134222 being conducted?
This trial has 16 study locations across California, Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.